Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Generic Drugs Pricing Strategies

Differing Dynamics Demonstrated In UK As Duo Double In October

Pricewatch UK – October 2021

  • Data

Executive Summary

Two generics saw their average UK trade prices almost double in October for very different reasons, according to the latest pricing information from market researcher WaveData.

You may also be interested in...



Topiramate Tablets Dominate November Rises In UK

Topiramate tablets took four places in our table of average UK generic price rises for November 2021, as prices as much as trebled for the epilepsy treatment. However, one product ranked even higher with a 231% average price rise.

Indoramin Increase Tops UK Rises In September

Benign prostatic hyperplasia treatment indoramin topped the UK’s steepest generic price rises in September with an average price that more than trebled, according to the latest figures from WaveData.

Shortlist Revealed Ahead Of October Awards

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.

Table

View full table

Topics

Tags:
Market Intelligence Generic Drugs Pricing Strategies
Latest Headlines

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

Shortlist Revealed Ahead Of October Awards

Teva Looks To Novartis To Replace Departing Dethlefs

US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla

See All
UsernamePublicRestriction

Register

GB151411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By